Señales en vivo de DMYD-B.ST | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 04:27):

Stats
Volumen de hoy	43 535.00
Volumen promedio	276 985
Capitalización de mercado	1.03B
EPS	SEK0 ( 2023-10-11 )
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-8.18
ATR14	SEK0.121 (1.09%)

Volumen Correlación

Largo: 0.16 (neutral)

Corto: -0.46 (neutral)

Signal:(49.866) Neutral

Diamyd Medical AB (publ) Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Diamyd Medical AB (publ) Correlación - Moneda/Commodity

-0.23
( neutral )

-0.09
( neutral )

0.00
( neutral )

-0.28
( neutral )

0.11
( neutral )

0.70
( moderate )

Diamyd Medical AB (publ) Finanzas

Annual	2023
Ingresos:	SEK546 000
Beneficio Bruto:	SEK-3.09M (-565.57 %)
EPS:	SEK-1.480

FY	2023
Ingresos:	SEK546 000
Beneficio Bruto:	SEK-3.09M (-565.57 %)
EPS:	SEK-1.480

FY	2022
Ingresos:	SEK454 000
Beneficio Bruto:	SEK-3.95M (-869.82 %)
EPS:	SEK-1.130

FY	2021
Ingresos:	SEK253 000
Beneficio Bruto:	SEK-2.25M (-888.54 %)
EPS:	SEK0.868

Financial Reports:

No articles found.

Diamyd Medical AB (publ)

Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was incorporated in 1984 and is based in Stockholm, Sweden.